| 1 |
NCT02834234 |
Completed |
Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays |
|
- Genetic: comparative genomic analysis
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
|
33 |
All |
18 Years and older (Adult, Senior) |
NCT02834234 |
D50828 |
|
May 2013 |
January 2016 |
January 2016 |
July 15, 2016 |
July 26, 2016 |
|
|
| 2 |
NCT01590472 |
Completed |
Do Your Genes Put You at a Higher Risk of Developing Mesothelioma |
|
|
Observational |
|
- Wake Forest University
- University of Pennsylvania
- Mayo Clinic
- (and 5 more...)
|
Other |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- Creation of a consortium of investigators (6 sites) for collection of blood for germline DNA and demographic information from 1000 mesothelioma subjects.
- GWAS will be performed on the DNA from the 1000 subjects with mesothelioma and compared with 1000 age and asbestos exposure matched controls free of past personal history and family history of cancer.
|
69 |
All |
18 Years and older (Adult, Senior) |
NCT01590472 |
GTS 36076 MARF |
|
June 2011 |
December 2014 |
December 2015 |
May 3, 2012 |
November 7, 2017 |
|
- Johns Hopkins University
Baltimore, Maryland, United States - Mayo Clinic
Rochester, Minnesota, United States - New York University School of Medicine
New York, New York, United States - (and 3 more...)
|
| 3 |
NCT01356251 |
Active, not recruiting |
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma |
|
- Behavioral: Questionnaires & online virtual support group
|
Interventional |
Not Applicable |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- To describe the psychological needs of patients with mesothelioma.
- the aim is to explore the acceptability and promise of an Internet-based discussion group for patients with mesothelioma.
|
107 |
All |
18 Years and older (Adult, Senior) |
NCT01356251 |
11-066 |
|
May 2011 |
November 2019 |
November 2019 |
May 19, 2011 |
April 18, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
| 4 |
NCT02603315 |
Completed |
Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM) |
- Malignant Pleural Mesotheliomas
|
- Other: marker CD74 and vascular endothelial growth factor VEGF
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival
- assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result of CD 74
|
50 |
All |
39 Years to 84 Years (Adult, Senior) |
NCT02603315 |
DR-81 |
VITMPM |
October 2015 |
May 2016 |
May 2016 |
November 11, 2015 |
June 1, 2016 |
|
- Ain Shams University Hospital
Cairo, Egypt
|
| 5 |
NCT03007030 |
Recruiting |
Trial of Adcetris in CD30+ Malignant Mesothelioma |
- Lung Diseases Due to External Agents
- Mesothelioma
|
- Drug: Brentuximab Vedotin
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Seattle Genetics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Control Rate (DCR) in Pre-Treated Participants with Unresectable Malignant Pleural Mesothelioma (MPM) Treated with Brentuximab Vedotin
- Time to Progression in Pre-Treated Participants with Unresectable Malignant Pleural Mesothelioma (MPM) Treated with Brentuximab Vedotin
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT03007030 |
2016-0514
NCI-2017-00069 |
|
April 5, 2017 |
April 2022 |
April 2023 |
December 30, 2016 |
March 14, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 6 |
NCT02395679 |
Unknown † |
Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients |
|
- Biological: MesoCancerVac
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective is to establish a tolerable dose of MesoCancerVac in patients with malignant mesothelioma
- The secondary objective is the evaluation of an immune response after MesoCancerVac
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT02395679 |
NL44330.000.14 |
MesoCancerVa |
January 2015 |
December 2015 |
December 2016 |
March 23, 2015 |
March 23, 2015 |
|
- Erasmus MC, Dept. of Pulmonary Medicine
Rotterdam, Zuid-Holland, Netherlands
|
| 7 |
NCT03075527 |
Recruiting |
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma |
|
- Drug: Tremelimumab
- Drug: Durvalumab
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Overall Survival
- Progression Free Survival
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT03075527 |
16-549 |
|
April 10, 2017 |
September 30, 2020 |
September 30, 2024 |
March 9, 2017 |
January 19, 2018 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
| 8 |
NCT01721018 |
Completed |
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. |
- Malignant Pleural Mesothelioma
|
- Biological: HSV1716 Intra-pleural delivery
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of HSV1716 given by single and repeat intrapleural administration in patients with inoperable malignant pleural mesothelioma.
- Obtain evidence of HSV1716 replication and lysis of malignant pleural mesothelioma cells through analysis of pleural fluid and serum samples for evidence of cell death and/or HSV1716 replication and/or changes in appropriate biomarkers.
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT01721018 |
1716-12 |
1716-12 |
October 2012 |
November 14, 2016 |
November 14, 2016 |
November 2, 2012 |
June 9, 2017 |
|
- Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, South Yorkshire, United Kingdom - Queen Elizabeth Univeristy Hospital, NHS Greater Glasgow & Clyde Health Board
Glasgow, United Kingdom
|
| 9 |
NCT02611037 |
Recruiting |
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
- Mesothelioma
|
- Drug: Cisplatin
- Drug: Methotrexate
- Drug: Gemcitabine
- Other: Lung Cancer Symptom Scale for Mesothelioma Questionnaire
|
Interventional |
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR)
- Overall Survival (OS)
- Progression Free Survival (PFS)
- (and 2 more...)
|
36 |
All |
18 Years and older (Adult, Senior) |
NCT02611037 |
MCC-18094 |
|
January 4, 2016 |
December 2018 |
December 2019 |
November 20, 2015 |
December 14, 2017 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
| 10 |
NCT02029105 |
Completed |
Serum Biomarkers in Diagnosis of Mesothelioma |
|
- Biological: Mesothelin, hyaluronan, osteopontin, syndecan-1
|
Observational |
|
- Eskisehir Osmangazi University
|
Other |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Serum N-ERC/mesothelin, C-ERC/mesothelin, hyaluronan, osteopontin and syndecan -1 level in the patients with mesothelioma, metastatic malignant pleural diseases, benign pleural diseases, and benign asbestos pleurisy.
|
230 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02029105 |
2010-280-1 |
|
January 2004 |
December 2010 |
October 2013 |
January 7, 2014 |
January 7, 2014 |
|
- ESOGU Lung and Pleural Cancer Application and Research Center
Eskisehir, Turkey
|
| 11 |
NCT03436732 |
Recruiting |
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma |
|
- Drug: LMB-100
- Drug: SEL-110
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- safety and tolerability
- maximum tolerated dose
- descriptive statistics of pharmacokinetic parameters including half life, clearnace, AUC, volume of distribution
- (and 2 more...)
|
20 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT03436732 |
180057
18-C-0057 |
|
February 28, 2018 |
November 29, 2019 |
November 30, 2020 |
February 19, 2018 |
March 22, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 12 |
NCT01870609 |
Terminated |
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Drug: defactinib (VS-6063)
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Compare the overall survival (OS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo
- Compare the progression free survival (PFS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo
- To assess Quality of Life (QoL) in subjects treated with defactinib (VS-6063) or placebo using the Lung Cancer Symptom Scale modified for mesothelioma (LCSS-Meso)
- To determine the objective response rate (ORR) in subjects receiving defactinib (VS-6063) or placebo.
|
344 |
All |
18 Years and older (Adult, Senior) |
NCT01870609 |
VS-6063-202 |
COMMAND |
September 2013 |
January 2016 |
January 2016 |
June 6, 2013 |
January 30, 2017 |
|
- University of California San Francisco Medical Center
San Francisco, California, United States - Cleveland Clinic Florida
Weston, Florida, United States - University of Chicago Medical Center
Chicago, Illinois, United States - (and 70 more...)
|
| 13 |
NCT02899195 |
Recruiting |
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma |
- Mesothelioma
- Pleural Mesothelioma
|
- Drug: Concurrent Durvalumab
- Drug: Maintenance Durvalumab
|
Interventional |
Phase 2 |
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
- Progression-Free Survival (PFS)
- (and 2 more...)
|
55 |
All |
18 Years and older (Adult, Senior) |
NCT02899195 |
PrE0505
ESR-15-10792 |
PrE0505 |
June 13, 2017 |
August 2020 |
December 2020 |
September 14, 2016 |
April 11, 2018 |
|
- University San Diego Moores Cancer Center
La Jolla, California, United States - Ronald Reagan UCLA Medical Center
Los Angeles, California, United States - Stanford Cancer Institute
Stanford, California, United States - (and 16 more...)
|
| 14 |
NCT02300883 |
Active, not recruiting |
Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients |
|
|
Observational |
|
- Armando Santoro, MD
- Istituto Clinico Humanitas
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- dissect the molecular mechanisms underlying the development of malignant mesothelioma
- study of the effect of TAMs
- investigation of molecular mechanisms linking macrophages
- (and 3 more...)
|
100 |
All |
Child, Adult, Senior |
NCT02300883 |
ONC/OSS-02/2011 |
|
April 2011 |
December 2017 |
January 2018 |
November 25, 2014 |
November 6, 2017 |
|
- Istituto Clinico Humanitas
Rozzano, Milano, Italy - Istituto Clinico Humanitas
Rozzano, Milan, Italy
|
| 15 |
NCT01024946 |
Completed
Has Results |
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity |
- Malignant Pleural Mesothelioma
|
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Novartis Pharmaceuticals
- Dana-Farber Cancer Institute
- University of Pennsylvania
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To Determine the Rate of Clinical Benefit (i.e. Rate of Complete or Partial Response Plus Stable Disease) at 16 Weeks for Patients With Malignant Mesothelioma Treated With Everolimus as Second or Third Line Therapy.
|
11 |
All |
18 Years and older (Adult, Senior) |
NCT01024946 |
09-142 |
|
December 2009 |
July 2012 |
July 2012 |
December 3, 2009 |
May 12, 2015 |
April 20, 2015 |
- Dana Farber Cancer Institute
Boston, Massachusetts, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 16 |
NCT01719068 |
Unknown † |
Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos |
|
|
Observational |
|
- British Columbia Cancer Agency
- BC Cancer Foundation
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Development of Model to Predict Workers at highest risk of lung cancer/mesothelioma
|
200 |
All |
50 Years to 79 Years (Adult, Senior) |
NCT01719068 |
H12-01812 |
|
October 2012 |
October 2014 |
December 2014 |
November 1, 2012 |
November 1, 2012 |
|
- British Columbia Cancer Agency
Vancouver, British Columbia, Canada
|
| 17 |
NCT02139904 |
Recruiting |
Vinorelbine in Mesothelioma |
|
- Drug: Vinorelbine
- Other: Active Symptom Control
|
Interventional |
Phase 2 |
- Wales Cancer Trials Unit
- Pierre Fabre Laboratories
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Progression Free Survival
- Number of serious adverse events reported
- BRCA1 status in blood and tumour samples
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02139904 |
UNOLE 0329 |
VIM |
March 1, 2016 |
March 1, 2018 |
December 1, 2018 |
May 15, 2014 |
April 11, 2017 |
|
- Wales Cancer Trials Unit
Cardiff, United Kingdom
|
| 18 |
NCT01812148 |
Completed |
Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) |
|
- Procedure: Cytoreductive surgery and HIPEC
|
Observational |
|
- Maisonneuve-Rosemont Hospital
|
Other |
- Observational Model: Case-Crossover
- Time Perspective: Retrospective
|
- Overall survival
- Disease-Free survival
|
19 |
All |
Child, Adult, Senior |
NCT01812148 |
Maisonneuve Rosemont Hospital
12112 |
|
January 2012 |
March 2013 |
March 2013 |
March 18, 2013 |
March 18, 2013 |
|
- Maisonneuve Rosemont Hospital
Montréal, Quebec, Canada
|
| 19 |
NCT02991482 |
Recruiting |
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma |
- Pleural Mesothelioma Malignant Advanced
|
- Drug: Pembrolizumab
- Drug: Gemcitabine
- Drug: Vinorelbine
|
Interventional |
Phase 3 |
- European Thoracic Oncology Platform
- Merck Sharp & Dohme Corp.
- Frontier Science Foundation, Hellas
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) in patients with advanced pre-treated malignant mesothelioma.
- Objective response.
- Overall survival.
- (and 3 more...)
|
142 |
All |
18 Years and older (Adult, Senior) |
NCT02991482 |
ETOP 9-15
2016-002062-31
3475-594 |
PROMISE-meso |
September 12, 2017 |
December 2020 |
December 2020 |
December 13, 2016 |
February 20, 2018 |
|
- ICO Hospitalet
Barcelona, Spain - Hospital Teresa Herrera
La Coruña, Spain - Hospital Clínico Universitario de Valladolid
Valladolid, Spain - (and 12 more...)
|
| 20 |
NCT02838745 |
Recruiting |
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas |
|
- Drug: Pemetrexed
- Drug: Cisplatin
|
Interventional |
Phase 1 |
- Baylor College of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Safety Maximum Tolerated Dose of HIOC with cisplatin and pemetrexed for Malignant Pleural Mesothelioma.
|
36 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02838745 |
H-36460 |
|
September 2016 |
July 2018 |
August 2018 |
July 20, 2016 |
October 27, 2017 |
|
- Baylor St Lukes
Houston, Texas, United States
|
| 21 |
NCT00685204 |
Unknown † |
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma |
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
|
- To determine the objective response rate of milataxel when given orally to previously treated patients with malignant mesothelioma.
- To evaluate time to progression, duration of tumor response and safety and tolerability of TL139 treatment.
|
90 |
All |
18 Years and older (Adult, Senior) |
NCT00685204 |
TL139204 |
TL139 |
March 2008 |
|
|
May 28, 2008 |
May 28, 2008 |
|
- Rush University Medical Center
Chicago, Illinois, United States - University of Chicago
Chicago, Illinois, United States - New York University Cancer Center
New York, New York, United States
|
| 22 |
NCT03068117 |
Active, not recruiting |
Malignant Mesothelioma - Can we Improve Quality of Life |
|
- Other: Regular Early Specialist Symptom Control Treatment (RESSCT)
|
Interventional |
Not Applicable |
- Portsmouth Hospitals NHS Trust
- British Lung Foundation
- University of Oxford
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- EORTC C-30 Quality of Life
- Health Related Quality of Life (HRQoL) in Patients
- Patient Mood
- (and 5 more...)
|
319 |
All |
18 Years and older (Adult, Senior) |
NCT03068117 |
PHT/2013/46 |
RESPECT-Meso |
March 2014 |
March 2017 |
May 2017 |
March 1, 2017 |
March 3, 2017 |
|
- Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia - County Durham and Darlington NHS Foundation Trust
County Durham, Durham, United Kingdom - Basildon and Thurrock University Hospitals NHS Foundation Trust - Basildon Hospital
Basildon, Essex, United Kingdom - (and 16 more...)
|
| 23 |
NCT02707666 |
Recruiting |
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma |
|
- Drug: Pembrolizumab
- Drug: Cisplatin and Pemetrexed
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Gamma-Interferon Gene Expression profile (GEP) response rate defined as an increase beyond the median value of the sum of individual genes
- Number of participants with adverse events as measured by CTCAEv4.0
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT02707666 |
IRB15-1149 |
|
February 2016 |
March 2018 |
September 2018 |
March 14, 2016 |
January 4, 2018 |
|
- University of Chicago
Chicago, Illinois, United States
|
| 24 |
NCT00386815 |
Completed |
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Drug: pemetrexed
- Drug: cisplatin
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To investigate safety profile when administered pemetrexed combined with cisplatin in malignant pleural mesothelioma patients
- To investigate efficacy when administered pemetrexed combined with cisplatin in malignant pleural mesothelioma patients
|
20 |
All |
20 Years to 75 Years (Adult, Senior) |
NCT00386815 |
10512
H3E-JE-ME02 |
|
October 2006 |
|
February 2007 |
October 12, 2006 |
April 11, 2007 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Aichi, Japan - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fukuoka, Japan - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Hokkaido, Japan - (and 4 more...)
|
| 25 |
NCT00859469 |
Unknown †
Has Results |
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma |
|
- Drug: Oxaliplatin/Gemcitabine
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Best Response
- Overall Survival
- Progression-free Survival
|
29 |
All |
18 Years and older (Adult, Senior) |
NCT00859469 |
AAAA2861 (Final) |
|
April 2004 |
March 2009 |
March 2013 |
March 11, 2009 |
February 24, 2012 |
February 24, 2012 |
- Columbia University Medical Center
New York, New York, United States
|
| 26 |
NCT02385812 |
Recruiting |
Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma |
|
- Procedure: Low-dose computed tomography Annual scan x3
- Procedure: Low-dose computed tomography Baseline scan only
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Change in SF-12 quality of life score
- Change in EQ-5D and STAI
- Lung cancer detection rate
- Mesothelioma detection rate
|
200 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT02385812 |
10007822 |
|
April 2015 |
December 2019 |
December 2019 |
March 11, 2015 |
October 6, 2017 |
|
- University of Calgary
Calgary, Alberta, Canada - University of Alberta
Edmonton, Alberta, Canada
|
| 27 |
NCT00787410 |
Completed |
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the activity of ZD1839 in patients with malignant mesothelioma by estimating the objective response rate (CR and PR) at trial closure
- To further characterize the safety profile of ZD1839 at a 250mg daily dose
- To estimate PFS (progression free survival)
- (and 2 more...)
|
23 |
All |
18 Years and older (Adult, Senior) |
NCT00787410 |
1839IL/0094 |
|
September 2003 |
April 2008 |
April 2008 |
November 7, 2008 |
June 6, 2012 |
|
|
| 28 |
NCT02761863 |
Not yet recruiting |
Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Other: CD 74, VEGF detection
|
Observational |
|
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- CD 74 and VEGF detection effect on response to treatment
|
100 |
All |
19 Years to 70 Years (Adult, Senior) |
NCT02761863 |
CURE001 |
|
July 30, 2019 |
January 30, 2020 |
July 30, 2021 |
May 4, 2016 |
February 23, 2018 |
|
|
| 29 |
NCT03213301 |
Recruiting |
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. |
- Malignant Pleural Mesothelioma, Advanced
|
|
Interventional |
Phase 2 |
- Swiss Group for Clinical Cancer Research
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS) at 12 weeks
- Progression-free survival (PFS)
- Objective response (OR)
- (and 3 more...)
|
43 |
All |
18 Years and older (Adult, Senior) |
NCT03213301 |
SAKK 17/16
2017-001016-11 |
|
September 28, 2017 |
July 1, 2019 |
March 1, 2022 |
July 11, 2017 |
February 1, 2018 |
|
- Kantonsspital Baden
Baden, Switzerland - IOSI Ospedale Regionale di Bellinzona e Valli
Bellinzona, Switzerland - Kantonsspital Graubuenden
Chur, Switzerland - (and 3 more...)
|
| 30 |
NCT01353482 |
Withdrawn |
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Drug: Cisplatin
- Drug: Pemetrexed
- Drug: Vorinostat
- Drug: Placebo
|
Interventional |
Phase 1
Phase 2 |
- University College, London
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Phase I only - Dose-limiting toxicities
- Phase I only - Number of cycles of pemetrexed-cisplatin given
- Phase II only - Progression free survival
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT01353482 |
UCL/08/0359
2009-013638-26 |
MESO-02 |
|
|
|
May 13, 2011 |
March 22, 2012 |
|
|
| 31 |
NCT00469196 |
Completed |
Tomotherapy Treatment for Mesothelioma |
|
|
Interventional |
Phase 2 |
- AHS Cancer Control Alberta
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Quality of Life
- Breathing Function
- Survival/Response Rate
|
18 |
All |
18 Years and older (Adult, Senior) |
NCT00469196 |
LU-11-0077 / 22933 |
|
October 2006 |
May 2015 |
May 2015 |
May 4, 2007 |
April 6, 2016 |
|
- Cross Cancer Institute
Edmonton, Alberta, Canada
|
| 32 |
NCT02519049 |
Recruiting |
11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM) |
|
|
Observational |
|
- Istituto Clinico Humanitas
|
Other |
- Time Perspective: Prospective
|
- Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing talc pleurodesis
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02519049 |
1287 |
|
September 2014 |
September 2017 |
November 2017 |
August 10, 2015 |
November 21, 2016 |
|
- Istituto Clinico Humanitas
Rozzano, Milano, Italy
|
| 33 |
NCT01160458 |
Completed
Has Results |
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy |
- Pleural Mesothelioma
- Peritoneal Mesothelioma
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Response Rate (PR+CR)
- Safety of IMC-A12 in Patients With Mesothelioma
- Duration of Overall Response
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT01160458 |
100146
10-C-0146 |
|
June 2, 2010 |
August 13, 2016 |
February 24, 2017 |
July 12, 2010 |
April 10, 2018 |
May 14, 2013 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 34 |
NCT00402766 |
Completed |
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma |
|
- Drug: Cisplatin
- Drug: Imatinib Mesylate
- Drug: Pemetrexed
- Drug: Dexamethasone
|
Interventional |
Phase 1 |
- M.D. Anderson Cancer Center
- Novartis
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Cisplatin, Pemetrexed, and Imatinib Mesylate Given to Participants with Unresectable or Metastatic Malignant Mesothelioma
|
19 |
All |
18 Years and older (Adult, Senior) |
NCT00402766 |
2005-0288
NCI-2012-01381 |
|
August 2006 |
February 2014 |
February 2014 |
November 22, 2006 |
November 18, 2015 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 35 |
NCT02194231 |
Recruiting |
ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) |
- Malignant Pleural Mesothelioma
|
|
Interventional |
Phase 2 |
- Mario Negri Institute for Pharmacological Research
- PharmaMar
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival - PFS12w
- Progression Free Survival (PFS)
- Overall survival (OS)
- (and 8 more...)
|
141 |
All |
18 Years and older (Adult, Senior) |
NCT02194231 |
IRFMN-MPM-6077
2011-006330-16 |
ATREUS |
July 2013 |
November 2018 |
November 2018 |
July 18, 2014 |
March 29, 2018 |
|
- Azienda ospedaliera ss. Antonio e Biagio e Cesare Arrigo
Alessandria, AL, Italy - Cliniche Humanitas Gavazzeni
Bergamo, BG, Italy - Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
Bologna, Bo, Italy - (and 6 more...)
|
| 36 |
NCT03269227 |
Recruiting |
Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Radiation: Accelerated hypofractionation with Tomotherapy
|
Interventional |
Not Applicable |
- Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
- Overall survival (OS)
- Disease control rate (DCR)
- time to progessione (TTP)
|
30 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT03269227 |
IRST163.01 |
MesoRT |
August 14, 2017 |
July 2020 |
July 2020 |
August 31, 2017 |
September 11, 2017 |
|
- SC Radiotherapy
Meldola, Italy
|
| 37 |
NCT00969098 |
Unknown † |
Response Evaluation in Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
|
Observational |
|
- Istituto Clinico Humanitas
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- To validate a semi-automated iterative threshold-based region growing algorithm in a previously published series of patients.
- To extend the analysis to another series of consecutive patients with MALIGNANT PLEURAL MESOTHELIOMA treated with first-line pemetrexed-based chemotherapy, and to perform a combined analysis of the two groups.
- To validate the new liver-based threshold semi-automated algorithm on the GE ADW4.6 workstation with the algorithm validated in step 1 in the same subset of patients.
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT00969098 |
ONC/OSS-02/2009 |
|
June 2009 |
August 2015 |
September 2015 |
August 31, 2009 |
August 6, 2015 |
|
- Istituto Clinico Humanitas
Rozzano, Milano, Italy
|
| 38 |
NCT02588131 |
Unknown † |
A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) |
- Pleural Mesothelioma
- Peritoneal Mesothelioma
|
- Drug: tremelimumab plus MEDI4736
|
Interventional |
Phase 2 |
- Italian Network for Tumor Biotherapy Foundation
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- immune-related (ir)- objective response rate (ORR)
- Immune-related-Disease control rate (ir-DCR)
- Disease control rate (DCR)
- (and 8 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02588131 |
NIBIT-MESO-1 |
|
October 2015 |
June 2016 |
March 2018 |
October 27, 2015 |
October 27, 2015 |
|
- Medical Oncology and Immunotherapy Division, University Hospital of Siena
Siena, Italy
|
| 39 |
NCT01627795 |
Suspended |
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment |
|
- Drug: Oshadi D and Oshadi R
|
Interventional |
Phase 1
Phase 2 |
- Oshadi Drug Administration
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse events and serious adverse events occurence
- overall survival time
|
17 |
All |
21 Years and older (Adult, Senior) |
NCT01627795 |
OS-MES-P2-01 |
|
December 2016 |
August 2018 |
December 2018 |
June 26, 2012 |
April 18, 2018 |
|
- Hadassah Medical Center
Jerusalem, Israel
|
| 40 |
NCT01279967 |
Unknown † |
A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
|
Interventional |
Phase 2 |
- Barts & The London NHS Trust
- Cancer Research UK
- UK: Barts Center for Experimental Cancer Medicine (CECM) for Trial Coordination
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- progression-free survival
- response rate
- overall survival
- (and 2 more...)
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT01279967 |
6837
2006-004592-35 |
ADAM |
January 2011 |
January 2015 |
March 2015 |
January 20, 2011 |
November 20, 2014 |
|
- The Royal Sussex County Hospital
Brighton, United Kingdom - Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
Cambridge, United Kingdom - Hull and East Yorkshire Hospitals NHS Trust,The Princess Royal Hospital
Hull, United Kingdom - (and 4 more...)
|
| 41 |
NCT00509041 |
Completed
Has Results |
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma |
|
|
Interventional |
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 24 Week Progression Free Survival
- Number of Participants With Overall Tumor Response
- Overall Survival
- Progression Free Survival
|
46 |
All |
18 Years and older (Adult, Senior) |
NCT00509041 |
CALGB-30601
U10CA031946
CDR0000558362 |
|
August 2007 |
February 2010 |
December 2012 |
July 31, 2007 |
August 11, 2016 |
January 17, 2013 |
- Rebecca and John Moores UCSD Cancer Center
La Jolla, California, United States - UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States - Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware, United States - (and 34 more...)
|
| 42 |
NCT00137826 |
Completed |
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma |
|
- Drug: Erlotinib
- Drug: Bevacizumab
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- Massachusetts General Hospital
- University of Chicago
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the response to the combination of bevacizumab and erlotinib in previously treated malignant mesothelioma
- To determine the time to tumor progression
- to determine the duration of response
- (and 2 more...)
|
37 |
All |
18 Years and older (Adult, Senior) |
NCT00137826 |
03-369 |
|
February 2004 |
March 2007 |
July 2009 |
August 30, 2005 |
December 26, 2011 |
|
- The University of Chicago
Chicago, Illinois, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
| 43 |
NCT02639767 |
Withdrawn |
Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Drug: Pemetrexed/Cisplatin
- Radiation: Pleural Intensity Modulated Radiation Therapy
- Device: MRI
|
Interventional |
Phase 1 |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose limiting toxicities (DLT)
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT02639767 |
15-304 |
|
December 2015 |
December 2016 |
|
December 24, 2015 |
December 7, 2016 |
|
- Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States - (and 3 more...)
|
| 44 |
NCT03063450 |
Recruiting |
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma |
|
- Drug: Nivolumab
- Other: Placebo
|
Interventional |
Phase 3 |
- University of Southampton
- University of Leicester
- University of Sheffield
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall survival
- modified RECIST or RECIST 1.1 - progression free survival
- modified RECIST or RECIST 1.1 - overall response rate
- (and 3 more...)
|
336 |
All |
18 Years and older (Adult, Senior) |
NCT03063450 |
22864
2016-003111-35
CA290841
A21400 |
CONFIRM |
March 28, 2017 |
June 2021 |
July 2021 |
February 24, 2017 |
February 27, 2018 |
|
- Aberdeen Royal Infirmary
Aberdeen, United Kingdom - Royal Bournemouth Hospital
Bournemouth, United Kingdom - Velindre Cancer Centre
Cardiff, United Kingdom - (and 8 more...)
|
| 45 |
NCT01243632 |
Completed |
Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment |
- Malignant Pleural Mesothelioma
|
- Drug: Prolonged 6-hr infusion of gemcitabine
|
Interventional |
Phase 2 |
- Institute of Oncology Ljubljana
- Ministry of Higher Education, Science and Technology, Solvenia
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Safety and tolerability
|
78 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT01243632 |
86/12/02 |
|
December 2002 |
June 2010 |
June 2010 |
November 18, 2010 |
November 18, 2010 |
|
- Institute of Oncology Ljubljana
Ljubljana, Slovenia
|
| 46 |
NCT01869023 |
Active, not recruiting |
Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma |
- Advanced Malignant Pleural Mesothelioma
|
- Drug: Gemcitabine
- Drug: Cisplatin
|
Interventional |
Phase 2 |
- Instituto Nacional de Cancerologia de Mexico
- National Council of Science and Technology, Mexico
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate adverse effects to 250 mg/m2 infusion gemcitabine
- Progression Free Survival
- overall survival
|
26 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01869023 |
INCANOGAR2012-JA3 |
|
November 2010 |
December 2017 |
December 2017 |
June 5, 2013 |
March 3, 2017 |
|
- Instituto Nacional de Cancerología
Mexico City, Mexico
|
| 47 |
NCT01649024 |
Unknown † |
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma |
|
|
Interventional |
Phase 2 |
- Azienda Ospedaliera Universitaria Senese
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective tumor response by modified Response Evaluation Criteria in Solid Tumor (RECIST)
- Disease control rate
- Progression free survival
- Safety
|
29 |
All |
18 Years and older (Adult, Senior) |
NCT01649024 |
MESOT-TREM-2008
2008-005171-95 |
|
May 2009 |
June 2012 |
June 2013 |
July 25, 2012 |
July 25, 2012 |
|
- Medical Oncology and Immunotherapy Unit, University Hospital of Siena
Siena, Italy
|
| 48 |
NCT01604005 |
Terminated |
PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma |
|
- Radiation: Prophylactic Irradiation of Tracts (PIT)
|
Interventional |
Phase 3 |
- Brynn Chappell
- The Christie NHS Foundation Trust
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Incidence of chest wall tract metastasis 6 months from randomisation
- Time from randomisation to chest wall tract metastasis
- Position of chest wall tract metastasis recurrence in relation to radiotherapy field in patients randomised to experimental arm (in field/out-of-field)
- (and 2 more...)
|
375 |
All |
18 Years and older (Adult, Senior) |
NCT01604005 |
08_DOG07_93
ISRCTN04240319
PB-PG-1010-23232 |
PIT |
July 2012 |
April 5, 2017 |
April 5, 2017 |
May 23, 2012 |
January 29, 2018 |
|
- Tameside General Hospital
Ashton-Under-Lyne, United Kingdom - Basingstoke & North Hampshire Hospital
Basingstoke, United Kingdom - Clatterbridge Cancer Centre
Bebington, United Kingdom - (and 57 more...)
|
| 49 |
NCT01241682 |
Completed |
Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma |
- Malignant (Pleural) Mesothelioma
|
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- number of cytotoxic T cells and regulatory T cells in the blood of patients
- safety and toxicity
|
10 |
All |
Child, Adult, Senior |
NCT01241682 |
NL24050.000.08 |
PMR-MM-002 |
October 2009 |
October 2011 |
October 2012 |
November 16, 2010 |
February 27, 2014 |
|
- Erasmus Medical Center
Rotterdam, Zuid-Holland, Netherlands
|
| 50 |
NCT01112293 |
Completed |
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma |
- Pleural Malignant Mesothelioma
|
|
Interventional |
Phase 2 |
- Abramson Cancer Center of the University of Pennsylvania
|
Other |
- Primary Purpose: Treatment
|
- 3-month PFS rate
- Estimate the distribution of progression-free and over survival
|
14 |
All |
18 Years and older (Adult, Senior) |
NCT01112293 |
UPCC 03510 |
|
April 2010 |
October 2012 |
December 2014 |
April 28, 2010 |
August 2, 2017 |
|
- Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
Create an RSS feed from your search for:
Download the search results for: